Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK.
Grant McCarthyKate YoungMatthew Madin-WarburtonTyler MantaianElizabeth BrookKaylie MetcalfeJan MikelsonRuifeng XuCarl Seyla-HammerRaquel Aguiar-IbáñezMayur AmonkarPublished in: Journal of medical economics (2024)
This model demonstrates pembrolizumab provides a valuable new alternative therapy for UK patients with MSH-H/dMMR cancer at the cost of £32,085 per QALY, with confidential discounts anticipated to improve cost-effectiveness further.